GlobeNewsWire
12 Jul 2026, 10:28 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
HMB-002 clinical data demonstrated proof of mechanism in Von Willebrand Disease, showing dose-dependent increases in VWF and FVIII of 2.4-fold or more. — Strong clinical proof of mechanism for a first-in-class treatment typically triggers significant positive valuation for clinical-stage biotech companies.
+0.80Hemab Therapeutics introduced HMB-003, a non-hormonal direct plasmin inhibitor targeting heavy menstrual bleeding and other bleeding settings. — Expanding the pipeline into a high-prevalence market (heavy menstrual bleeding) increases the company's total addressable market.
+0.50HMB-002 data supports a potential monthly subcutaneous dosing schedule due to the durability of its effects. — Improved dosing convenience (monthly vs frequent) significantly increases the competitive advantage and commercial viability of a drug.
+0.40Which stocks this story touches
Continue reading
6 related stories
Top 2 movers · tap to explore
The company presented positive clinical data for HMB-002 and introduced a new program, HMB-003, for heavy menstrual bleeding.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
13h ago
